Logo image
Analgesic Response to Intravenous Ketamine Is Linked to a Circulating microRNA Signature in Female Patients With Complex Regional Pain Syndrome
Journal article   Open access   Peer reviewed

Analgesic Response to Intravenous Ketamine Is Linked to a Circulating microRNA Signature in Female Patients With Complex Regional Pain Syndrome

Sabrina R Douglas, Botros B Shenoda, Rehman A Qureshi, Ahmet Sacan, Guillermo M Alexander, Marielle Perreault, James E Barrett, Enrique Aradillas-Lopez, Robert J Schwartzman and Seena K Ajit
The journal of pain, v 16(9), pp 814-824
Sep 2015
PMID: 26072390
url
https://doi.org/10.1016/j.jpain.2015.05.008View
Published, Version of Record (VoR)Open Access (Publisher-Specific) Open

Abstract

MicroRNA complex regional pain syndrome biomarker ketamine
Although ketamine is beneficial in treating complex regional pain syndrome (CRPS), a subset of patients respond poorly to therapy. We investigated treatment-induced microRNA (miRNA) changes and their predictive validity in determining treatment outcome by assessing miRNA changes in whole blood from patients with CRPS. Blood samples from female patients were collected before and after 5 days of intravenous ketamine administration. Seven patients were responders and 6 were poor responders. Differential miRNA expression was observed in whole blood before and after treatment. In addition, 33 miRNAs differed between responders and poor responders before therapy, suggesting the predictive utility of miRNAs as biomarkers. Investigation of the mechanistic significance of hsa-miR-548d-5p downregulation in poor responders showed that this miRNA can downregulate UDP-glucuronosyltransferase UGT1A1 mRNA. Poor responders had a higher conjugated/unconjugated bilirubin ratio, indicating increased UGT1A1 activity. We propose that lower pretreatment levels of miR-548d-5p may result in higher UDP-GT activity, leading to higher levels of inactive glucuronide conjugates, thereby minimizing the therapeutic efficacy of ketamine in poor responders. Differences in miRNA signatures can provide molecular insights distinguishing responders from poor responders. Extending this approach to other treatment and outcome assessments might permit stratification of patients for maximal therapeutic outcome. This study suggests the usefulness of circulating miRNAs as potential biomarkers. Assessing miRNA signatures before and after treatment demonstrated miRNA alterations from therapy; differences in miRNA signature in responders and poor responders before therapy indicate prognostic value. Mechanistic studies on altered miRNAs can provide new insights into disease. •We studied ketamine treatment–induced miRNA alterations in blood from patients with CRPS.•Differential miRNA expression was observed in whole blood before and after treatment.•Before therapy, 33 miRNAs differed between responders and poor responders.•Lower pretreatment levels of miR-548d-5p may contribute to higher UDP-GT activity.•Circulating miRNAs can be potential biomarkers in predicting treatment response.

Metrics

20 Record Views
43 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Clinical Neurology
Neurosciences
Logo image